Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Institute of Cancer Research, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Institute of Cancer Research, Medical Devices Deals, 2011 to YTD 2017 10
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deal Details 12
Private Equity 12
DRI Capital Acquires Partial Royalty Rights of Zytiga from Institute of Cancer Research 12
Partnerships 13
Merck Serono Enters into Co-Development Agreement with Institute of Cancer Research and Wellcome Trust 13
Nuevolution Enters Into Agreement With Cancer Research Technology And Institute Of Cancer Research For Drug Discovery 14
Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 16
Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 17
Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 18
Cancer Research Technology, Institute of Cancer Research And ZoBio Enter Into Agreement To Develop Cancer Drugs 20
Licensing Agreements 21
Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 21
Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 22
Institute of Cancer Research Enters Into Licensing Agreement With Dotmatics For Informatics Platform 24
Institute of Cancer Research – Key Competitors 25
Institute of Cancer Research – Key Employees 26
Institute of Cancer Research – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Government and Public Interest 28
Nov 16, 2017: ICR responds to NICE approval of new breakthrough drugs on the NHS for women with advanced breast cancer 28
Nov 07, 2017: NCRI 2017: Big data analysis predicts risk of radiotherapy effects 29
Sep 22, 2017: New treatment approach for rare type of triple negative breast cancers identified 30
Sep 10, 2017: Merck ‘Grant for Oncology Innovation’ awards recognize recipients for pushing boundaries in oncology research 32
Sep 05, 2017: New approach could better predict breast cancer risk due to family history 33
Aug 29, 2017: Bowel cancer study reveals impact of mutations on protein networks 35
Aug 02, 2017: Targeted radiotherapy limits side effects of breast cancer treatment 37
Jul 10, 2017: Scientists call for better use of chemical tools to improve cancer drug discovery 39
Jul 10, 2017: ICR awarded £30 million towards new Centre for Cancer Drug Discovery 40
May 30, 2017: Pioneering genetic research into myeloma is spearheading our search for new treatments 41
May 29, 2017: New genetic cause of kidney cancer in children discovered 42
May 16, 2017: Scientists build molecule to disrupt cancer protein 43
Mar 27, 2017: Largest ever brain cancer study reveals new secrets to inherited risk 44
Mar 27, 2017: ICR scientists awarded £1.5m precision medicine funding for targeted, less toxic childhood cancer treatments 46
Jan 12, 2017: Scientists discover powerful new inhibitor of cancer stress signal 47
Nov 24, 2016: New research uncovers mechanism for genetic risk of myeloma 49
Oct 26, 2016: Promising target for triple-negative breast cancers 50
Aug 22, 2016: Effect of combined HRT on breast cancer risk likely to have been underestimated, new study finds 51
Aug 09, 2016: Radiotherapy supercharges cancer-targeting viruses to treat deadly skin cancer 53
Jun 14, 2016: Targeted radiotherapy for head and neck cancer could reduce the risk of dry mouth 54
May 01, 2016: New cancer drugs could treat lethal resistant prostate cancers 55
Mar 10, 2016: Gene may worsen cancer outcome by speeding metabolism of drugs 57
Feb 02, 2016: Plans unveiled for UK’s new global hub for cancer research and treatment 59
Product News 62
Jun 06, 2017: New chemotherapy approach offers breast cancer patients a better quality of life 62
Appendix 63
Methodology 63
About GlobalData 63
Contact Us 63
Disclaimer 63
Institute of Cancer Research, Pharmaceuticals & Healthcare, Key Facts 2
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Institute of Cancer Research, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Institute of Cancer Research, Deals By Therapy Area, 2011 to YTD 2017 9
Institute of Cancer Research, Medical Devices Deals, 2011 to YTD 2017 10
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
DRI Capital Acquires Partial Royalty Rights of Zytiga from Institute of Cancer Research 12
Merck Serono Enters into Co-Development Agreement with Institute of Cancer Research and Wellcome Trust 13
Nuevolution Enters Into Agreement With Cancer Research Technology And Institute Of Cancer Research For Drug Discovery 14
Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 16
Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 17
Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 18
Cancer Research Technology, Institute of Cancer Research And ZoBio Enter Into Agreement To Develop Cancer Drugs 20
Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 21
Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 22
Institute of Cancer Research Enters Into Licensing Agreement With Dotmatics For Informatics Platform 24
Institute of Cancer Research, Key Competitors 25
Institute of Cancer Research, Key Employees 26
Institute of Cancer Research, Other Locations 27